期刊文献+

PPARγ在运动改善胰岛素抵抗中的作用 被引量:1

下载PDF
导出
摘要 胰岛素抵抗(insulin resistance,IR)是指机体产生胰岛素的量低于正常机体所需量的一种病理状态或单位浓度的胰岛素其细胞生物学效应减弱,代偿性引起胰岛8细胞分泌胰岛素量增加,继而引发的高胰岛素血症。运动可以改善IR已经得到共识,但是其分子机制仍然需要进一步的阐明。本文就过氧化物酶体增殖物激活受体γ(PPARγ)与胰岛素抵抗的关系及运动改善IR的分子机制做一综述,重点阐述运动与转录因子PPARγ表达方面的研究进展。
出处 《医学临床研究》 CAS 2012年第12期2382-2384,共3页 Journal of Clinical Research
  • 相关文献

参考文献22

  • 1Werman A,Hollenberg A,Solanes G. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma).Differential activity of PPARgamma1 and -2 isoforms and influence of insulin[J].Journal of Biological Chemistry,1997,(32):20230-20235.
  • 2Vidal-Puig AJ,Considine RV,Jimenez-Linan M. Peroxisome proliferator-activated receptor gene expression in human tissues Effects of obesity,weight loss,and regulation by insulin and glucocorticoids[J].Journal of Clinical Investigation,1997,(10):2416-2422.
  • 3Zhang B,Berger J,Hu E. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha[J].Molecular Endocrinology,1996,(11):1457-1466.
  • 4孙敏,刘超.过氧化物酶体增生物激活受体的特性及其在多种疾病中的作用[J].中国实用内科杂志,2004,24(7):446-448. 被引量:7
  • 5吴松华.核受体PPARγ与代谢综合征[J].第二军医大学学报,2003,24(5):526-527. 被引量:7
  • 6Buse JB,Rubin CJ,Frederich R. Muraglitazar,a dual (alpha/gamma) PPAR activator:a randomized,double-blind,placebo-controlled,24-week monotherapy trial in adult patients with type 2 diabetes[J].Clinical Therapeutics,2005,(08):1181-1195.doi:10.1016/j.clinthera.2005.08.005.
  • 7Wolford JK,Vozarova de Courten B. Genetic basis of type 2 diabetes mellitus:implications for therapy[J].Treatments in Endocrinology,2004,(04):257-267.
  • 8Okuno A,Tamemoto H,Tobe K. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats[J].Journal of Clinical Investigation,1998,(06):1354-1361.
  • 9Miles PD,Barak Y,He W. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency[J].Journal of Clinical Investigation,2000,(03):287-292.
  • 10环奕,申竹芳.选择性PPARγ调节剂治疗糖尿病的研究新进展[J].中国药理学通报,2008,24(2):149-152. 被引量:11

二级参考文献58

  • 1衣雪洁.运动对胰岛素抵抗相关疾病的影响[J].沈阳体育学院学报,2005,24(2):8-11. 被引量:8
  • 2陈娜,吴英良.PPARδ的结构及其生物学功能与疾病[J].中国药理学通报,2006,22(9):1035-1038. 被引量:11
  • 3Matsuda J, Hosoda K, Itoh H, et al. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes. Diabetes, 1998,47(11):1809-1814
  • 4Yang W, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferatoractivated receptor - (γ) agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabet Care,2002,25(2):376-380
  • 5Lee HJ,Choi SS, Park MK, et al. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.Biochem Biophys Res Commun, 2002,296(2):293-299
  • 6Torra IP, Chinetti G, Duval C, et al. Peroxisome proliferator-activated receptors:from transcriptional control to clinical practice. Curr Opin Lipiol,2002,12(3):245-254
  • 7Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun ,2002,293 (5): 1431-1437
  • 8Hsueh WA,Javkson S,Law RE. Control of vascular cell proliferation and migration by PPARγ. Diabet Care ,2001,24(2):392-397
  • 9Kwak BR, Myit S, Mulhanpt F, et al. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class Ⅱ induction in atheroma-associated cells. Circ Res,2002,90(3):356-362
  • 10Castrillo A, Mojena M, Hortelano S, et al. Peroxisome proliferator-activated receptor-gamma independent inhibition of macrophage activation by the non-thiazolidinedizone agonist L-796,449, comparison with the effects of 15-deoxy-delta(12,14) -prostaglandi

共引文献36

同被引文献11

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部